Clinical Core

摘要 这一临床核心将首次在人类正电子发射计算机断层扫描成像中使用针对α-突触核蛋白(α-SYN)的新放射性示踪剂 4个重复tau(4R Tau)。放射性示踪剂将在Med Chem Core和项目中进行临床前开发 1和2分别聚焦于α-SYN和4R tau。我们将把α-SYN放射性示踪剂集中在两种联体核病上， 帕金森病(PD)和多系统萎缩(MSA)，以及焦点4R tau放射性示踪剂在两个不同的 突变导致的进行性核上性瘫痪(PSP)和家族性额颞叶痴呆(FTD) 微管相关蛋白Tau(MAPT)基因。我们将吸引参与者，并与多个正在进行的 FTD、PSP、PD和MSA的临床队列。 临床核心职能包括与执行委员会的互动，以确定何时开始人类 研究，协调放射性示踪剂候选者所需的监管活动，进行早期安全评估 包括宾夕法尼亚大学的全身剂量研究；协调患者选择标准，集中收集和服务 所有成像和人口统计数据，为人类协调示踪动力学方法的开发和验证 成像，并协调所有数据，以有效地实现对候选放射性示踪剂的Go-Nogo决策。 α-SYN的放射性示踪剂将在两种不同的联核病中进行测试，PD和MSA，而4R tau 放射性示踪剂将在PSP和FTD患者中进行测试。作为对候选人的诊断和特异性的最终检查 放射性示踪剂，我们将要求所有患者允许死后脑捐赠用于脑放射自显影 新鲜冰冻脑组织上的相关放射性示踪剂。此外，此核心将与多个持续进行的 研究PD、MSA、PSP和FTD的队列研究。最后，强大的数据共享计划有助于协作 以及支持文件和成像数据的使用。

ABSTRACT This Clinical Core will implement first in human PET imaging with new radiotracers targeting α-synuclein (α-syn) and 4 repeat tau (4R tau). Radiotracers will be developed pre-clinically in the Med Chem Core and in Projects 1 and 2 focusing on α-syn and 4R tau, respectively. We will focus α-syn radiotracers on two synucleinopathies, Parkinson disease (PD) and Multiple Systems Atrophy (MSA), and focus 4R tau radiotracers on two different tauopathies, progressive supranuclear palsy (PSP) and familial frontotemporal dementias (FTD) due to mutation in Microtubule Associated Protein Tau (MAPT) gene. We will draw participants and interact with multiple ongoing clinical cohorts of FTD, PSP, PD and MSA. The Clinical Core functions include interaction with the Executive Committee to determine when to start human studies, coordinate required regulatory activities for radiotracer candidates, carry out early safety assessments including whole body dosimetry studies at Penn; coordinate patient selection criteria, centrally collect and serve all imaging and demographic data, coordinate tracer kinetic methods development and validation for human imaging, and coordinate all data to efficiently enable GO-NOGO decisions for candidate radiotracers. Radiotracers for α-syn will be tested in two different synucleinopathies, PD and MSA whereas, 4R tau radiotracers will be tested in PSP and FTD patients. As a final check on diagnosis and specificity of candidate radiotracers, we will request all patient participants to permit postmortem brain donation for autoradiography of relevant radiotracers on fresh frozen brain tissues. Additionally, this Core will interact with multiple ongoing studies with cohorts studying PD, MSA, PSP and FTD. Finally, a robust data sharing plan facilitates collaboration and use of support documents and imaging data.